Factors Influencing CAR-T Therapy in AML and the Future of Off-the-Shelf T-cells

Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy that poses many challenges for diagnosis and treatment. While the treatment landscape of AML has improved in recent years due to advances in therapy, there are still several hurdles to overcome to improve the efficacy of these novel agents.

In this podcast, you will hear from leading experts John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, and Rizwan Romee, MD, Dana-Farber Cancer Institute, Boston, MA, who share some insights on the challenges of CAR-T therapy in AML and strategies to overcome these. The experts also discuss CAR-NK therapy, NK-cell transduction, patient response to CAR-T therapy, and more. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.

The post CAR-T therapy in AML: challenges and future outlooks appeared first on VJHemOnc.